Restrictive IL-10 induction by an innocuous parainfluenza virus vector ameliorates nasal allergy - 18/04/17
Doi : 10.1016/j.jaci.2016.05.044
Keiichi Yamanaka, MD a, ∗ 
, Takehisa Nakanishi, MD a, ∗, Kana Isono, MS b, ∗, Chisami Hasegawa, MD a, ∗, Hiroyasu Inada, MD c, Kento Mizutani, MD a, Yoshiaki Matsushima, MD a, Karin Okada, MD a, Tomotaka Mabuchi, MD d, Makoto Kondo, MD a, Akisa Yamagiwa, MD a, Masato Kakeda, MD a, Koji Habe, MD a, Tetsuya Nosaka, MD e, Esteban C. Gabazza, MD f, Hidetoshi Yamazaki, DDS b, Hitoshi Mizutani, MD a, Mitsuo Kawano, PhD e
, Takehisa Nakanishi, MD a, ∗, Kana Isono, MS b, ∗, Chisami Hasegawa, MD a, ∗, Hiroyasu Inada, MD c, Kento Mizutani, MD a, Yoshiaki Matsushima, MD a, Karin Okada, MD a, Tomotaka Mabuchi, MD d, Makoto Kondo, MD a, Akisa Yamagiwa, MD a, Masato Kakeda, MD a, Koji Habe, MD a, Tetsuya Nosaka, MD e, Esteban C. Gabazza, MD f, Hidetoshi Yamazaki, DDS b, Hitoshi Mizutani, MD a, Mitsuo Kawano, PhD e a Department of Dermatology, Mie University, Graduate School of Medicine, Tsu, Mie, Japan
b Department of Stem Cell and Developmental Biology, Mie University, Graduate School of Medicine, Tsu, Mie, Japan
c Faculty of Pharmaceutical Science, Department of Pathology, Suzuka University of Medical Science, Minamitamagaki, Suzuka, Mie, Japan
d Department of Dermatology, Tokai University School of Medicine, Shimokasuya, Isehara, Kanagawa, Japan
e Department of Microbiology and Molecular Genetics, Mie University, Graduate School of Medicine, Tsu, Mie, Japan
f Department of Immunology, Mie University, Graduate School of Medicine, Tsu, Mie, Japan
| K.Y. (grant nos. 23591643 and 26461690) and H.M. (grant no. 24591647) received grants for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Japan. K.Y. received a grant from the Mie University Hospital Seed Grant Program 2014 and 2015. The rest of the authors did not receive any financial support for the present study. |
|
| Disclosure of potential conflict of interest: K. Yamanaka has received grants from the Ministry of Education, Culture, Sports, Science and Technology, the Mie University Hospital Seed Grant Program, Kyowa Hakko Kirin Co Ltd, Janssen Pharmaceutical KK, MSD Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation and has received payment for lectures from Kyowa Hakko Kirin, Janssen Pharmaceutical KK, Mitsubishi Tanabe, Maruho, AbbVie, Novartis, GlaxoSmithKline, Torii, EIZAI, and Leo. T. Nakanishi, C. Hasegawa, K. Mizutani, Y. Matsushima, K. Okada, M. Kondo, A. Yamagiwa, and K. Habe have received grants from Kyowa Hakko Kirin Co, Janssen Pharmaceutical KK, MSD Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation. T. Mabuchi has received grants from Kyowa Hakko Kirin Co, Janssen Pharmaceutical KK, MSD Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation; has received payment for lectures from Kyowa Hakko Kirin, Janssen, Mitsubishi Tanabe, Maruho, Leo, Novartis, Ushio, Torii, and Eli Lilly. M. Kakeda has received grants from GlaxoSmithKline. T. Nosaka has stock/stock options in BioComo, Inc. E. C. Gabazza has received grants from Astellas Pharmaceuticals, Asahi Pharma, Shionogi Pharmaceuticals, Aqua Therapeutics, Iwade Research Institute of Mycology, and Suntory Holdings. H. Yamazaki has received a grant from Challenging Exploratory Research from the Japanese Society for the Promotion of Science. H. Mizutani has received a grant from the Ministry of Education, Culture, Sports, Science, and Technology, Kyowa Hakko Kirin Co, Janssen Pharmaceutical KK, MSD Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Eizai, POLA Pharma, Kinoshokuhinkenkyus ho. Co Ltd, MSD Co Ltd, AbbVie, GlaxoSmithKline, Japan Tissue Engineering, Shionogi Co Ltd, Kaken Pharma Co Ltd, Ono Pharm Co Ltd, Daiichi Sankyo Co Ltd, Eli Lilly Japan KK, Nippon Pharma Co Ltd, Japan Blood Products Organization, Maruho Co Ltd, Teijin Pharma, and Boehringer Ingelheim; has received payment for lectures from Kyowa Hakko Kirin Co Ltd, Janssen Pharmaceutical KK, Mitsubishi Tanabe, Maruho, AbbVie, Novartis, GlaxoSmithKline, EIZAI, Taisho Toyama, POLA, Absolute Co Ltd, Actelion, Bayer Yakuhin, Cracie Pharma, Daiichi-Sankyo, Eli Lilly, Garderma, JIMRO, Kaken, Kao, KCI, Kissei, Leo, Nippon Kasei Chemical Co Ltd, Roht Pharm. Co Ltd, Shionogi Co Ltd, Sumitomo Dainippon Pharma Co Ltd, Torii, and Tsumara; has received payment for manuscript preparation from Maruishi and Medical Review Co Ltd; is a patent coholder for Caspase-1 Tg mouse through Taiho Pharmaceutical Co Ltd; has received royalties from Oriental Yeast Co Ltd; and has received payment for the development of educational presentations from Maruho Co Ltd. M. Kawano has received a grant from Japan BCG Laboratory. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 2
P. 682 - février 2017 Retour au numéro
Article précédent
- IgE-reactivity profiles to nonspecific lipid transfer proteins in a northwestern European country
- Margaretha A. Faber, Athina L. Van Gasse, Ine I. Decuyper, Astrid Uyttebroek, Vito Sabato, Margo M. Hagendorens, Chris H. Bridts, Luc S. De Clerck, Montserrat Fernandez-Rivas, Mariona Pascal, Araceli Diaz-Perales, Didier G. Ebo
- Allergy-related disease in relation to early life exposures—the ALADDIN birth cohort
- Helena Marell Hesla, Fredrik Stenius, Hans Järnbert-Pettersson, Johan Alm
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?